InnovAge
InnovAge's revenue rose 15.9% to $990 million in fiscal 2026. Its operating margin was 0.3%, up from −3.5% a year earlier. Free cash flow was $50 million, up 89.5%. The diluted share count rose 0.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What InnovAge does
InnovAge runs health care centers for frail older adults, many of whom qualify for both Medicare and Medicaid. It does this through the Program of All-Inclusive Care for the Elderly, known as PACE. The program covers a wide range of services: in-home care, primary care, therapy, dental and mental health care, meals, activities, transportation and care management. The goal is to keep participants living at home as long as it is safe.
InnovAge is paid a set amount per participant, a model called capitated care, and it contracts directly with government payors such as Medicare and Medicaid. It has one reportable segment, PACE. Under its contracts it takes on the risk that the cost of care will be higher than the payment. As of June 30, 2026, it served approximately 8,230 participants and operated 20 centers in California, Colorado, Florida, New Mexico, Pennsylvania and Virginia.
The company is based in Denver, Colorado. It went public in March 2021.
Its biggest risks, as it describes them
- Under its PACE contracts it takes on all the risk that care will cost more than it is paid.
- It depends on Medicare and Medicaid, and cuts to funding or changes in the rules could hurt it.
- Its growth plans, including opening centers and making acquisitions, may not work as expected.
- Government rules for PACE and the yearly payment rates can change.
Income statement
InnovAge lost money in fiscal 2026: a net loss of $2 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 184 | 174 | 103 | 106 | 141 |
| Debt incl. finance leases | 86 | 88 | 83 | 73 | 63 |
| Net debt (negative means net cash) | −98 | −86 | −20 | −33 | −78 |
| Net debt to EBITDA | −10.3x | — | — | — | −3.3x |
| Debt to equity | 0.3x | 0.3x | 0.3x | 0.3x | 0.3x |
| Interest coverage | −1.7x | −12.4x | −5.7x | −6.8x | 0.6x |
| Current ratio | 2.3x | 1.4x | 1.2x | 1.1x | 1.1x |
| Quick ratio | 2.3x | 1.4x | 1.2x | 1.1x | 1.1x |
Cash flow
Projections
Project InnovAge's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought InnovAge shares on the open market, and 2 insiders sold $92.7 million, $207,182 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | Nicole DamatoChief Legal Officer | Sold plan | 23,814 | $8.70 | $207,182 | Form 4 |
| Sep 24, 2026 | Ignite Aggregator Lp10% owner | Sold | 10,000,000 | $9.25 | $92.5 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 | FY26 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 6 of 9 | 6 of 9 |
| Rule of 40 | 5.1% | 14.9% | 21.0% |
| Altman Z'' | 0.90 | 0.08 | 0.40 |
| Accruals ratio | 2.8% | −11.8% | −12.4% |
The nine F-score tests
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Pass | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 9 | 6 of 9 | 6 of 9 |
Compare
Put InnovAge side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| InnovAge | FY26 | 15.9% | 0.3% | 5.1% | 0.7% | −3.3x | 6 | |
| Guardant Health | FY25 | 32.9% | −44.5% | −23.7% | −188.8% | — | 4 | Compare |
| CorVel | FY26 | 7.0% | — | 11.5% | — | — | — | Compare |
| Pennant Group | FY25 | 36.3% | 5.5% | 3.8% | 9.3% | 2.6x | 5 | Compare |
| Sotera Health | FY25 | 5.7% | — | 12.8% | 6.7% | — | 7 | Compare |
7 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 567 | 638 | 699 | 688 | 764 | 854 | 990 |
| Revenue growth | — | 12.4% | 9.5% | −1.5% | 11.0% | 11.8% | 15.9% |
| Gross profit | — | — | 135 | 101 | 132 | 154 | 228 |
| Research and development | — | — | — | — | — | — | — |
| Operating income | 51 | −12 | −4 | −49 | −23 | −30 | 3 |
| Net income | 26 | −44 | −6 | −41 | −21 | −30 | −2 |
| Diluted EPS (US$) | 0.19 | −0.36 | −0.05 | −0.30 | −0.16 | −0.22 | −0.02 |
| Diluted shares (millions) | 135 | 124 | 136 | 136 | 136 | 135 | 136 |
| Cash flow | |||||||
| Cash from operations | 44 | −8 | 27 | 20 | −37 | 33 | 65 |
| Capital expenditure | 12 | 18 | 38 | 23 | 8 | 6 | 14 |
| Free cash flow | 32 | −25 | −11 | −3 | −45 | 27 | 50 |
| Dividends paid | 0 | 10 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 78 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 24 | 5 | 0 |
| Stock-based compensation | 0 | 2 | 4 | 5 | 7 | 8 | 7 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 113 | 202 | 184 | 174 | 103 | 106 | 141 |
| Debt incl. finance leases | 218 | 85 | 86 | 88 | 83 | 73 | 63 |
| Total assets | 410 | 532 | 556 | 567 | 548 | 527 | 557 |
| Total liabilities | 302 | 174 | 202 | 253 | 248 | 264 | 289 |
| Shareholders' equity | 101 | 335 | 332 | 296 | 269 | 235 | 236 |
| Margins and ratios | |||||||
| Gross margin | — | — | 19.4% | 14.7% | 17.3% | 18.0% | 23.0% |
| Operating margin | 9.0% | −1.9% | −0.6% | −7.2% | −3.0% | −3.5% | 0.3% |
| Net margin | 4.6% | −6.9% | −0.9% | −5.9% | −2.8% | −3.5% | −0.3% |
| Free cash flow margin | 5.6% | −3.9% | −1.6% | −0.5% | −5.9% | 3.1% | 5.1% |
| Rule of 40 (growth + FCF margin) | — | 8.5% | 8.0% | −2.0% | 5.1% | 14.9% | 21.0% |
| Return on capital | — | −4.5% | −1.5% | −17.1% | −7.7% | −10.2% | 0.7% |
| Return on equity | — | −20.2% | −2.0% | −12.9% | −7.5% | −12.0% | −1.1% |
| Return on assets | — | −9.3% | −1.2% | −7.2% | −3.8% | −5.6% | −0.5% |
| Net debt to EBITDA | 1.7x | — | −10.3x | — | — | — | −3.3x |